On the evening of March 23, the local cro / cdmo leader Wuxi Apptec Co.Ltd(603259) disclosed the annual report of 2021.
The annual report shows that Wuxi Apptec Co.Ltd(603259) achieved an operating revenue of 22.902 billion yuan in 2021, with a year-on-year increase of 38.50%; The net profit was 5.097 billion yuan, a year-on-year increase of 72.19%; The basic earnings per share is 1.75 yuan. The company plans to distribute a cash dividend of 5.1740 yuan (including tax) for every 10 shares.
Wuxi Apptec Co.Ltd(603259) provides new drug R & D and production services for global pharmaceutical, biotechnology and medical device companies, covering the whole process from concept generation to commercial production.
As for the reasons for the performance growth, Wuxi Apptec Co.Ltd(603259) said that it was mainly due to the company’s continuous focus on giving play to the synergy of the unique “integrated, end-to-end” crdmo business model, strengthening the business diversion between platforms, providing customers with high-quality services and products, and the service demand of customers around the world for the company maintained a good growth.
According to the data, in 2021, Wuxi Apptec Co.Ltd(603259) added more than 1660 customers and more than 5700 active customers.
It is noteworthy that the Wuxi Apptec Co.Ltd(603259) annual report predicts that the revenue growth of the chemical business segment in 2022 will nearly double that of 2021, and the revenue growth of the testing business segment and the biology business segment in 2022 will continue the momentum of recent years; Cell and gene therapy ctdmo business is expected to continue the strong growth momentum in the fourth quarter of 2021, exceeding the growth rate of the industry.
However, it is expected that the R & D service department in China will meet the requirements of new drug R & D in 2022.
Looking forward to the future, Dr. Li Ge, chairman and CEO of Wuxi Apptec Co.Ltd(603259) said that the company will continue to strengthen capacity and scale building globally and continuously increase investment in new molecular R & D capacity. The company plans to invest RMB 9-10 billion in capital expenditure in 2022, increase the layout of new capacity and continue to promote the future development of the company Wuxi Apptec Co.Ltd(603259) will continue to be an unswerving enabler, help global partners accelerate the process of new drug research and development, seek well-being for patients, and realize the great vision of “making the world free of difficult drugs and difficult diseases” as soon as possible.
